Original Article |
1 Institute of Biomedical Technologies, National Council of Research, Pisa, Italy
2 Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milan, Italy
Correspondence: Maria Cristina Magli and Sergio Ottolenghi, MCM, Istituto di Tecnologie Biomediche-CNR, Via Moruzzi 1, 56124 Pisa, Italy/Dipartimento di Biotecnologie e Bioscienze, Università degli Studi Milano-Bicocca, Piazza della Scienza 2, 20126 Milano, Italy. E-mail:mariacristina.magli{at}itb.cnr.it/sergio.ottolenghi{at}unimib.it
|
|
|---|
Design and Methods: In the present work we investigated whether the transgene is also expressed in hematopoietic stem cells of adult bone marrow and fetal liver. To this purpose, we tested, in long-term repopulating assays, cell fractions expressing different levels of green fluorescent protein within Kit-positive or SLAM-selected populations.
Results: The experiments demonstrated transgene expression in both fetal and adult hematopoietic stem cells and indicated that the transgene is transcribed at distinctly lower levels in hematopoietic stem cells than in pluripotent and committed progenitors.
Conclusions: These results, together with previous data, show that a limited subset of DNA sequences drives gene expression in number of stem cell types (hematopoietic stem cells, primordial germ cells, cardiac stem cells). Additionally, our results might help to further improve high level purification of hematopoietic stem cells for experimental purposes. Finally, as the Kit/green fluorescent protein transgene is expressed in multiple stem cell types, our transgenic model provides powerful in vivo system to track these cells during development and tissue regeneration.
Key words: Kit, hematopoietic stem cells, hematopoietic progenitor cells, transgenic mouse.
|
|
|---|
Kit encodes the membrane receptor of stem cell factor (SCF), a diffusible ligand. It is expressed in several stem cell types, such as primordial germ cells, neural stem cells of the eye, hematopoietic stem cells (HSC), and cardiac stem cells, and several types of early committed progenitors. In these cells, the function of Kit is important or even essential, as demonstrated by genetic mutants and functional studies.4–11 The expression of Kit in multiple stem cell types suggests that common transcriptional programs might regulate this gene in different stem cells. In previous work, we showed that a mouse Kit transgene is able to efficiently drive green fluorescent protein (GFP) expression in primordial germ cells and in immature hematopoietic cells, such as CFU-mix and BFU-E progenitor cells.12 In the present work, we investigated whether the transgene is expressed in fetal liver and adult bone marrow HSC. Our results show that the transgene is indeed expressed in a Kit+ cell type, capable of long-term hematologic reconstitution upon transplantation into irradiated recipients. The expression level of the transgene in HSC is distinctly lower than in other progenitors, a fact that might be exploited to further improve the purification of HSC. In conclusion, our transgene contains the major regulatory sequences required for Kit (Kit/GFP) expression in several types of stem and progenitor cells, thus providing a powerful model to study common stem cell transcriptional programs.
|
|
|---|
Flow cytometric analysis and cell sorting
Flow cytometric and cell sorting were performed by a MoFlo (DAKO-Cytomation) flow cytometer/cell sorter with Summit 4.3 and FACSAria software (Becton Dickinson, RD). Total adult bone marrow or fetal liver cells from Kit-GFP transgenic animals and from non-transgenic controls (obtained by disaggregation in phosphate-buffered saline) were incubated with appropriate labeled antibodies from BD-Pharmingen: phycoerythrin (PE)-labeled anti-mouse LY 6A/E (Sca-1) (D7); peridin chlorophyll-cyanin 5.5-labeled anti-mouse CD11b (Mac-1) (M1/70); allophycocyanin (APC)-labeled anti-mouse CD117 (Kit) (2B8); PE-labeled anti-mouse CD48 (HM48-1); APC-labeled anti-mouse Gr-1 (Ly-6G and Ly-6C) (RB6-8C5); biotin anti-mouse T-cell receptor beta chain (H57-597); and biotin anti-mouse CD45R/B220 (RA3-6B2). The PE-labeled anti-mouse CD41 (MWREG30) was from Santa Cruz. The PE anti-mouse CD71, (clone R 17127) and APC anti-mouse CD150 (SC15-12F12.2) were from Biolegend (San Diego, CA). All the analyses were performed with the Moflo flowcytometer cell sorter, except the one shown in Figure 1 for which a Cyan ADP (Dako) was used. Background fluorescence levels (autofluorescence) were defined by comparison to levels in appropriate non-transgenic control cells, stained with isotype control fluorochrome conjugate. For the analysis of the side population,13 bone marrow cells (3x106/mL) were incubated with Hoechst 33342 (Sigma), 5 µg/mL for 90 min at 37°C, either in the absence (experimental samples) or presence (control samples) of 50 µM verapamil. The cells were then washed four times with fresh culture medium (1% fetal calf serum in Dulbeccos modified Eagles medium), further incubated with labeled antibodies for 30 min at 4°C, washed again at 4°C and analyzed by Moflo (DAKO) with UV (350 nm), 630 nm and 488 nm lasers. Data from at least 1.5x106 live cells were acquired. Cell sorting of bone marrow or disaggregated fetal liver cells from heterozygous transgenic embryos (identified by their bright GFP fluorescence) was performed after APC-labeled anti-Kit staining, and Kit+ cells were fractionated on the basis of levels of GFP fluorescence. In order to sort signaling lymphocytic activation molecule (SLAM)-positive HSC, bone marrow cells were pre-enriched with a double density Ficoll gradient14 adapted for mouse cells, in which undifferentiated mononuclear cells are layered between 1.069 g/mL and 1.075 g/mL by centrifugation.
![]() View larger version (46K): [in a new window] [Download PPT slide] |
Figure 1. Experimental strategy for the evaluation of the HSC content of different fetal liver and bone marrow fractions. Bone marrow (panel A) and fetal liver (panel B) cell fractions of different GFP fluorescence were transplanted into irradiated mice. Reconstitution was evaluated by the proportion of fluorescent (i.e. transgenic) versus non-fluorescent (i.e. non-transgenic, from co-transplanted supporting bone marrow) CFU-mix type colony (panel C) obtained from in vitro clonogenic assays of the bone marrow of transplanted mice. Note the intense fluorescence of the CFU-mix type colony, versus the complete absence of fluorescence of the adjacent mature myeloid colony. FACS analysis of the same marrow (panel D) shows excellent agreement of the results with those obtained by colony assays. The negative bone marrow sample (panel D, right side) did not yield any fluorescent CFU-mix, whereas the positive sample (left) yielded 87% fluorescent CFU-mix type colonies.
|
-thioglycerol, methyl cellulose, bovine serum albumin, 5% fetal calf serum, iron-saturated transferrin, lecithin, oleic acid, cholesterol, 2 u/mL human recombinant erythropoietin, 10 ng/mL murine stem cell factor, and 10 ng/mL murine interleukin-3. Cultures were scored both in bright field and fluorescence at 2, 7, and 12 days with an inverted microscope by using standard criteria.
Bone marrow transplantation
BDF1 female recipient mice, 8–12 weeks old, were lethally irradiated with 830 rads (x-ray source). Two hours after irradiation, they were injected intravenously with different numbers of sorted fetal liver or bone marrow cells, and 5x104 to 2x105 (as specified in individual experiments) unsorted wild type bone marrow cells as support, resuspended in IMDM. Controls were injected with cell-free suspending medium. Engrafted animals were killed and analyzed 4–6 months after transplantation. For secondary transplants, 107 cells from primary reconstituted mice were injected intravenously into lethally irradiated secondary BDF1 recipients.
|
|
|---|
In previous research, both E11.5 fetal liver and adult bone marrow cells FACS-sorted for GFP (or GFP and Kit) expression were found to be highly enriched for CFU-mix and BFU-E; however, we did not ascertain GFP expression in HSC.12 To address this question, we selected cell populations with different GFP fluorescence levels from adult bone marrow and E12.5 fetal liver (Figures 1A and 1B), and tested each of them by in vitro colony assays,12 as well as by long-term in vivo repopulation studies in lethally irradiated mice (HSC assays) (Figure 1). For long-term repopulation studies, we transplanted FACS-sorted cell fractions at various concentrations (ranging from 100 to 50,000 cells) together with a fixed number (2x105 cells) of non-transgenic total bone marrow cells as a support. After at least 4 months, we assessed hematologic reconstitution in two ways (Figures 1C-D). First, bone marrow from the recipient mice was plated in methylcellulose cultures, and the proportion of GFP-expressing (versus non-expressing) CFU-mix colonies was evaluated (Figure 1C). Previous work had shown that over 90% of CFU-mix colonies from the transgenic line used here express GFP, thus the proportion of fluorescent CFU-mix colonies is expected to faithfully reflect the level of reconstitution of the bone marrow by GFP transgenic versus non-transgenic co-transplanted cells. Second, we analyzed the GFP expression (by FACS) of bone marrow from the transplanted mice. In general a high level of reconstitution, as measured by colony assays (over 90% of fluorescent colonies), was paralleled (Figure 1D) by a high level of fluorescent cells in the bone marrow of reconstituted mice (25–35%, note that most differentiated bone marrow cells do not express Kit/GFP) (see below and Online Supplementary Figures S1 and S2).
The pattern of GFP expression in adult bone marrow is rather complex. Over 90% of Kit+ cells are also GFP+; within the Kit+ population, the majority of the cells show high levels of fluorescence (GFPhigh cells), whereas a smaller proportion (GFPint cells) show lower levels of fluorescence, and are poorly separated from the minor Kit+/GFP– population. Within the Kit–/lineage marker (Lin)+ population, the analysis of GFP fluorescence (Online Supplementary Figure S1 and data not shown) showed that a large proportion of the Kit–/Lin+ cells are either completely GFP– or show much lower levels of GFP expression than Kit+ cells. In particular, 60–90% of Kit–/CD71 or Ter119+ cells (erythroid cells) are GFP–, as well as 90–95% of lymphoid cells (B220 and T-cell receptor positive cells, not shown); myeloid cells (Gr-1+ and CD11b+) express GFP at low levels. Interestingly, and unexpectedly, Kit+/CD71+ or Kit+/Gr-1+ double positive cells express very high levels of GFP, even higher than those shown in Kit+/CD71– or Kit+/Gr-1– cells (Online Supplementary Figure S1, panels viii and xii, compare the green line, i.e. Kit+/lin+ double positive, with the red and blue lines, i.e. Kit single positive and Kit–/lin+ cells, respectively). Similarly to bone marrow, in fetal liver (Online Supplementary Figure S2) Kit+ cells are divided into GFPhigh and GFPint cells (with very few GFP– cells); Kit–/Lin+ cells (largely erythroid, i.e. CD71+ or Ter119+ cells) are mostly (90%) GFP–, with a small proportion of weakly GFP+ cells (panel viii).
For colony assays and transplantation experiments, we FACS-sorted Kit+ cells based on their levels of GFP expression. Kit–/GFP+ cells were tested as well. Table 1 shows that most bone marrow progenitors, as assayed in vitro (CFU-mix, BFU-E), are contained in the GFPhigh fraction. In contrast, HSC are highly enriched in the bone marrow Kit+/GFPint fraction, as demonstrated by the hematologic reconstitution of most transplanted mice (Table 2). Bone marrow cells expressing intermediate levels of GFP efficiently reconstituted a total of 16 out of 23 transplanted animals (Table 2, Kit+/GFPint and GFPint fractions). In contrast, only four out of 22 recipients were repopulated by the GFPhigh fractions (Table 2, Kit+/GFPhigh and GFPhigh cells). Furthermore, whereas 2x103–1x104 bone marrow Kit+/GFPint cells were sufficient to reconstitute four out of seven transplanted mice at a high level (35–50% of fluorescent CFU-mix), a comparable level of repopulation could be obtained only with 5x104 bone marrow Kit+/GFPhigh cells (Table 2 and Figure 2). As expected, mice that received Kit–/GFP+ cells did not show any reconstitution with fluorescent cells. To further confirm that the bone marrow reconstitution was really due to long-term repopulating cells, bone marrow from primary recipients was transplanted into secondary irradiated recipients. The results presented in Table 2 show that only bone marrow cells derived from GFPint transplanted mice were able to fully repopulate three out of four secondary recipients, whereas GFPhigh cells did not show reconstituting ability either in primary or secondary transplants. We also obtained similar conclusions by transplantation of fractionated E12.5 fetal liver cells (Figure 1B). Again, Kit+/GFPhigh fractions contained significantly more colony- forming cells than Kit+/GFPint fractions (Table 1). In contrast, upon transplantation Kit+/GFPint, but not Kit+/GFPhigh cell fractions (Figure 1), efficiently repopulated lethally irradiated mice (Table 2 and Figure 2B).
|
View this table: [in a new window] [Download PPT slide] |
Table 1. Hematopoietic precursors in the sorted cell fractions.
|
|
View this table: [in a new window] [Download PPT slide] |
Table 2. Long-term reconstitution of bone marrow by transplantation of cell fractions expressing different levels of green fluorescent protein.
|
![]() View larger version (19K): [in a new window] [Download PPT slide] |
Figure 2. Relative hematopoietic stem cells content of bone marrow and fetal liver cell fractions expressing different levels of GFP, as evaluated by long-term repopulation studies. Bone marrow long-term repopulation (4–5 months) by cell fractions from bone marrow (A) and fetal liver (B). Reconstitution was evaluated by the proportion of GFP– expressing CFU-mix type colonies obtained from the bone marrow of each transplanted mouse; GFP– colonies are assumed to derive from non-transgenic stem cells contained in the support bone marrow co-transplanted with the FACS-fractionated transgenic cells. Note that 90–100% of CFU-mix type colonies from untreated Kit/GFP mice express GFP12 The number of cells used for each transplant, and their level of GFP expression are shown. Fractions used are as exemplified in Figure 1. Kit– indicates GFP+ or GFP– cell fractions not expressing Kit; GFPint: Kit+ cells expressing intermediate levels of GFP; GFPhigh: Kit+ cells expressing high levels of GFP. The data for the transplantation of fetal liver cells refer to an experiment using cells pooled from 16 GFP+ livers (five pregnant females) at E12.5. The data for bone marrow are from four adult donor transgenic mice.
|
![]() View larger version (29K): [in a new window] [Download PPT slide] |
Figure 3. FACS analysis and separation of CD150+CD48–CD41– lineage-depleted cells on the basis of Kit/GFP expression. Total bone marrow from adult Kit/GFP mice (A) was depleted of lineage-positive cells (B). After lineage depletion, SLAM hematopoietic stem cells were gated as shown in (C); the right panel (D) represents the levels of GFP expression of CD150+CD48–CD41– hematopoietic stem cells-enriched fractions. GFP-negative (Neg), intermediate (Int) or high cells were gated (gates were set on the general GFP expression level shown in Online Supplementary Figure S1 and represented 8.92±1.80%, 57.77±4.60%, 33.10±2.52%, respectively. The same gating strategy was used for sorting (see Online Supplementary Figure S3).
|
|
View this table: [in a new window] [Download PPT slide] |
Table 3. Long-term reconstitution of bone marrow by transplantation of SLAM HSC expressing different levels of Kit/GFP.
|
|
|
|---|
The present results, together with other reports,9,12,23 now indicate that this transgene is expressed in a variety of stem cells, ranging from primordial germ cells to cardiac and hematopoietic stem cells, providing the basis for the elucidation of DNA sequences regulating a stem cell gene in multiple stem cell types.
Transgenic Kit/GFP is expressed in most hematopoietic Kit+ cells
The Kit/GFP transgene appears to be regulated correctly in early Kit+ hematopoietic progenitors. In fact, over 90% of cells in bone marrow fractions highly enriched in HSC and early progenitor cells, known to be Kit+ (SLAM HSC, CD150+, CD48–, CD41–),16,17 and side population Kit+/Sca1+ cells18,19 (Figure 3 and Online Supplementary Figure S4), show GFP expression. Similarly, most E12.5 fetal liver Kit+ cells, including Kit+/Sca1+/CD11b+ cells, which have the immunophenotype of fetal HSC,20–22 are also GFP+ (Online Supplementary Figure S5). The small proportion of Kit+/GFP- cells might represent cells in which the transgene is sporadically silenced by adjacent sequences due to its integration in a non-optimal chromatin environment.24
A proportion of Kit–/Lin+ cells, from both bone marrow and fetal liver, express GFP. Expression of GFP in these cells may either reflect transcription of the transgene in these cells, or persistence of GFP-mRNA and protein produced in Kit+ progenitors upstream to these cells. Although we cannot strictly rule out the possibility that some transcription of the Kit/GFP transgene occurs in Kit– cells, we favor the alternative possibility for several reasons. First, as exemplified in the erythroid lineage in bone marrow and fetal liver, most (60–90%, respectively) Kit–/CD71+ cells are GFP–, whereas the remainder show moderate GFP levels, much lower than those found in Kit+/CD71+ double positive and Kit+/CD71– early progenitor cells (Online Supplementary Figure S1, panel viii; Online Supplementary Figure S2, panel viii, compare Kit–/CD71+ cells (blue line) with Kit+/CD71– or Kit+/CD71+ cells, red and green, respectively). Similar data were also obtained in the myeloid lineage, as exemplified in bone marrow Kit–/Gr1+ cells (Online Supplementary Figure S1, panel xii) and Kit–/CD11b+, as well as in lymphoid B and T cells (data not shown). Second, these data are consistent with the results of our previous in vitro colony assays, which showed that colonies were homogeneously highly fluorescent during the early days of culture, whereas at later stages the fluorescence was greatly decreased (in erythroid colonies) or fully suppressed (in myeloid colonies12 see also Figure 1C). Thus, we suggest that, following its very efficient expression in the majority of early Kit+/Lin+ double positive hematopoietic progenitor cells, the transgene is downregulated in most of the more mature cell types, which progressively dilute, over successive cell divisions, the GFPmRNA and protein produced at high levels in early progenitors. Persistence of some GFP, but not Kit, in differentiated cells, may also be explained by the presence in hematopoietic cells of abundant micro RNA mir 221 and 222 (data not shown), which target Kit mRNA25 but not Kit/GFP mRNA, and might thus cause much faster turnover of Kit-mRNA than of Kit/GFP-mRNA.
Transgenic Kit/GFP is expressed in most hematopoietic stem cells
The transplantation experiments presented in Figures 1–3 and Tables 2 and 3 indicate that the Kit/GFP transgene is expressed in most bone marrow and fetal liver HSC. Unexpectedly, functional HSC are contained within cell fractions that express the transgene at intermediate levels. This is seen both using cells fractionated on the basis of Kit and Kit/GFP expression, and using cell fractions highly enriched in HSC on the basis of stringent SLAM-selection. In the latter case, most of the SLAM-selected GFP+ population are GFPint, and essentially all the HSC capable of long-term reconstitution are in this fraction (Figure 3, Table 3). Interestingly, cells selected less stringently for CD150, which are expected to contain lower proportions of HSC, show a higher proportion of GFPhigh versus GFPint cells (data not shown). These results are in agreement with the expression of Kit/GFP at intermediate levels also in cells with the immunopheno-type18,20–22 of HSC, such as side population Kit+/Sca1+ bone marrow cells and Kit+/Sca1+/CD11b+ fetal liver cells (Online Supplementary Figures S4 and S5). In contrast to HSC, progenitors such as CFU-mix and BFU-E express Kit/GFP at high levels (Table 1), as also do Kit+/Lin+ cells (Online Supplementary Figures S1 and S2). The basis for this surprising result is unknown. One possibility is that HSC are inherently less able than more downstream progenitors to transcribe Kit mRNA; this hypothesis may find some support from studies that showed that cell fractions with very low levels of Kit mRNA and protein could give efficient long-term bone marrow reconstitution.26–28 An alternative, perhaps more credible, hypothesis is that the Kit transgene, though capable of transcription in all types of Kit+ cells, may lack some of the regulatory elements that are required for optimal transcription in HSC, but not in other more downstream progenitors (see below). The distant 5' regulatory sequences29 discussed below are possible candidates for this role.
Finally, the observation that within SLAM-selected bone marrow cells16,17 almost all cells are GFP+, and the majority of HSC are GFPint, has some potential experimental applications. In fact, the precise gating for SLAM selection is a matter of discussion in HSC purification;30,31 selection for GFPint in conjunction with SLAM purification might thus help to further enrich in HSC the SLAM population.
The Kit/GFP transgene includes sequences controlling gene expression in different subsets of stem cells
The mouse Kit gene is a large gene extending for more than 100 Kb, and distant upstream deletions affect Kit activity.32 In spite of the large size of Kit, our present work demonstrates that a small subset of sequences, including a 6.7 Kb fragment of the promoter and 8 Kb of the first intron, is sufficient for expression in HSC, early progenitors and more mature Kit+ cells, indicating that a minimum complement of sequences essential for expression in HSC is contained in the transgene.
This finding will allow detailed characterization of the specific sequences responsible for Kit regulation in HSC. Upstream distant sequences (lying more than 100 Kb from the transcription start site) contact the Kit promoter-proximal intron region hypersensitive site 5 (HS5)12 (corresponding to the fragments present in our construct) in early erythroid progenitors grown in vitro, which express Kit.29 These sequences are then displaced upon induced differentiation and Kit repression.29 The transcription factor GATA1 may replace the GATA2 factor bound to a sequence in HS5 and may thus be instrumental in these chromatin changes and in repression.33 These data suggest that upstream sequences are involved in Kit activity,33 although, unexpectedly, large transgenic constructs including them are very poorly expressed in bone marrow cells.34
Notably, the upstream sequences are dispensable in our construct. It is possible that these sequences might be involved in a different level of regulation than the promoter and first intron sequences, perhaps controlling chromatin structure and accessibility of the proximal sequences to the transcriptional machinery, rather than directly affecting their activity. Alternatively, upstream sequences might play specific roles in different subsets of stem/progenitor cells. Addition of fragments of the upstream sequences to the presently defined transgenic sequences will allow their role to be tested in HSC versus downstream progenitors.
A few transgenic constructs have previously been shown to be expressed in HSC and/or early hematopoietic progenitors. These are based on regulatory sequences corresponding to genes encoding transcription factors such as Scl-Tal1,35,36 Runx137 and possibly GATA-238 and the membrane proteins Sca139 and CD34.40 All of these genes are coexpressed with Kit; SCL-Tal1 and Gata2 are thus potential regulators of Kit transcription.
A direct comparison between our results and those reported above is difficult, because of the differences in the reporter genes used, in the expression of the transgene in non-HSC populations and in the numbers and type of coinjected supporting cells used for transplantation. Overall, the data presented in Table 2 and Figure 2 show that the enrichment obtained with Kit+/GFPint cells is of a similar order to that reported by Silberstein et al. and Ma et al.36,39 Notably, as in our study, in these works the transgene was expressed in a large number of non-HSC/progenitor cells, a fact presumably reflecting the persistence in downstream cells of reporter mRNA/protein accumulated in earlier progenitors.
Expression of the Scl/Tal1 and Runx1 transgenes in HSC and other hematopoietic cells requires a subset of Scl/Tal1, GATA-2 and ETS binding sites;36,37,41 similar sites are also present in the Kit HS regions, although with different reciprocal arrangements than in the Scl/Tal1 gene. Further comparison and identification of common regulatory motifs between other stem cell genes and Kit will be important to define a critical regulatory network of gene expression in HSC.
The Kit gene is active in several types of stem cells, and its defects affect multiple cell lineages4 pointing to Kit being a pleiotropic, though cell-type-restricted, molecule. It would, therefore, be particularly relevant to have a mouse model in which the transgene efficiently recapitulates the activity of the endogenous molecule. The present Kit/GFP transgene, in addition to being expressed in HSC, is also active in primordial germ cells and subsets of spermatogonia,12,23 in early blastocysts grown in vitro and in embryonic stem cells (unpublished data: SO, LC and S. Dolci), and in a population of cardiac stem cells.9 Thus, Kit might be regulated by subsets of common transcriptional programs in different stem cells. Targets of the responsible transcription factors must lie within the relatively short regions encompassed by our transgene. Finally, transgene expression in HSC/progenitors has enabled monitoring of bone marrow cellular homing to muscle42 and heart (FC, unpublished data) following tissue damage. Thus, our transgenic mouse lines provide a powerful tool to shed light on aspects of cell trafficking and tissue regeneration, and on relationships with HSC.
FC performed bone marrow and fetal liver in vitro clonogenic assays and in vivo long-term repopulation assays, and statistical analysis of the experiments; LC, GL and SC performed cytofluorimetric analysis and sorting; FB helped in transplantation experiments; MCM and SO designed experiments and wrote the paper.
The authors reported no potential conflicts of interest.
Funding: this work was supported by grants from Progetto Nazionale Cellule Staminali, grant CS 73 (MCM and SO), MIUR-PNR grant RBNE01R4MJ-002 (MCM), Fondazione CARISBO grant 2005.9025 (MCM), Cofin MIUR 2005 (SO), and Fondazione CARIPLO 2005 (SO).
Received for publication July 29, 2008. Revision received September 24, 2008. Accepted for publication October 17, 2008.
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||